Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcadia Biosciences (RKDA) Equity Average (2016 - 2025)

Arcadia Biosciences filings provide 11 years of Equity Average readings, the most recent being $4.8 million for Q4 2025.

  • On a quarterly basis, Equity Average fell 41.47% to $4.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.8 million, a 41.47% decrease, with the full-year FY2025 number at $5.2 million, down 45.24% from a year prior.
  • Equity Average hit $4.8 million in Q4 2025 for Arcadia Biosciences, down from $5.0 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $44.2 million in Q2 2021 to a low of $4.8 million in Q4 2025.
  • Median Equity Average over the past 5 years was $16.9 million (2023), compared with a mean of $19.9 million.
  • Biggest five-year swings in Equity Average: skyrocketed 261.37% in 2021 and later crashed 54.06% in 2025.
  • Arcadia Biosciences' Equity Average stood at $35.7 million in 2021, then crashed by 35.7% to $23.0 million in 2022, then crashed by 38.8% to $14.1 million in 2023, then plummeted by 41.74% to $8.2 million in 2024, then plummeted by 41.47% to $4.8 million in 2025.
  • The last three reported values for Equity Average were $4.8 million (Q4 2025), $5.0 million (Q3 2025), and $6.7 million (Q2 2025) per Business Quant data.